DIA508.91-0.79 -0.16%
SPY739.22+1.67 0.23%
QQQ716.07+11.01 1.56%

Why Clover Health (CLOV) Stock Is Up Today

Barchart·06/04/2026 14:48:21
Listen to the news

CLOV Cover Image

What Happened?

Shares of health insurance company Clover Health (NASDAQ:CLOV) jumped 9.3% in the afternoon session after Canaccord Genuity raised its price target on the company's shares. 

Analyst Richard Close increased the firm's price target on Clover Health to $4.20 from $3.20 and maintained a Buy rating on the shares. The analyst commented that the firm's thesis for 2026 is materializing as a rising tide in managed care is benefiting digital health companies. According to the note, this was reflected in the stock's strong performance in April and May.

Is now the time to buy Clover Health? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Clover Health’s shares are extremely volatile and have had 36 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was 28 days ago when the stock gained 5.3% on the news that the company reported strong first-quarter 2026 results, returning to profitability and beating analyst expectations. 

Clover Health announced a significant improvement from the same quarter last year, posting earnings per share of $0.05, which was $0.02 ahead of consensus estimates. Revenue surged by 62% year-on-year to $749.2 million, also surpassing Wall Street's forecasts. The strong performance was reflected across the business, with the company's adjusted operating margin increasing by 5.6 percentage points compared to the prior year. 

Looking ahead, Clover Health issued full-year adjusted EBITDA guidance of $60 million at the midpoint, which was above analyst estimates.

Clover Health is up 65.8% since the beginning of the year, and at $4.00 per share, it is trading close to its 52-week high of $4.18 from May 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Clover Health’s shares 5 years ago would now be looking at only $443.89.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Contact Us

Contact Number :+852 3852 8500
Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hk
Online Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hk
Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2026 Webull Securities Limited. All rights reserved.